SpringerLink
Log in

What’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Cutaneous T-cell lymphomas are a heterogenous group of lymphomas that cause various skin manifestations. Severe pruritus occurs frequently in cutaneous T-cell lymphoma and negatively impacts patients’ quality of life. The pathophysiology of cutaneous T-cell lymphoma-associated itch is complex and involves various immune cells, inflammatory cytokines, and neuroimmune interactions. Treating cutaneous T-cell lymphoma pruritus can be challenging, and there have been few randomized controlled studies evaluating the use of antipruritic treatments in these patients. Systemic therapies targeting the disease have also been shown to have some antipruritic effects. Furthermore, although biologic therapy has revolutionized the treatment of other pruritic skin conditions, the use of biologics in cutaneous T-cell lymphoma remains controversial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021;7(1):61.

    Article  PubMed  Google Scholar 

  2. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70(2):205.e1-16.

    Article  PubMed  Google Scholar 

  3. Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol. 2012;51(8):930–4.

    Article  PubMed  Google Scholar 

  4. Wright A, Wijeratne A, Hung T, Gao W, Whittaker S, Morris S, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. J Pain Symptom Manag. 2013;45(1):114–9.

    Article  Google Scholar 

  5. Misery L. Pruritus in cutaneous T-cell lymphomas. In: Carstens E, Akiyama T, editors. Itch: mechanisms and treatment. Boca Raton (FL): CRC Press; 2014.

  6. Ottevanger R, van Beugen S, Evers A, Willemze R, Vermeer M, Quint K. Quality of life in patients with mycosis fungoides and Sézary syndrome: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2021;35(12):2377–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gonzalez BR, Zain J, Rosen ST, Querfeld C. Tumor microenvironment in mycosis fungoides and Sézary syndrome. Curr Opin Oncol. 2016;28(1):88–96.

    Article  CAS  Google Scholar 

  8. Serrano L, Martinez-Escala ME, Zhou XA, Guitart J. Pruritus in cutaneous T-cell lymphoma and its management. Dermatol Clin. 2018;36(3):245–58.

    Article  CAS  PubMed  Google Scholar 

  9. Hashimoto T, Nattkemper LA, Kim HS, Kursewicz CD, Fowler E, Shah SM, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol. 2021;30(6):804–10.

    Article  CAS  PubMed  Google Scholar 

  10. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–7.

    Article  CAS  PubMed  Google Scholar 

  11. Singer EM, Shin DB, Nattkemper LA, Benoit BM, Klein RS, Didigu CA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol. 2013;133(12):2783–5.

    Article  CAS  PubMed  Google Scholar 

  12. Möbs M, Gryzik S, Haidar A, Humme D, Beyer M, Vandersee S. Analysis of the IL-31 pathway in mycosis fungoides and Sézary syndrome. Arch Dermatol Res. 2015;307:479–85.

    Article  PubMed  Google Scholar 

  13. Cedeno-Laurent F, Singer EM, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015;158(1):1–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Nattkemper LA, Martinez-Escala M-E, Gelman AB, Singer EM, Rook AH, Guitart J, et al. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm Venereol. 2016;96(7):894–8.

    Article  CAS  PubMed  Google Scholar 

  15. Olszewska B, Żawrocki A, Gleń J, Lakomy J, Karczewska J, Zabłotna M, et al. Interleukin-31 is overexpressed in skin and serum in cutaneous T-cell lymphomas but does not correlate to pruritus. Postepy Dermatol Alergol. 2020;39(1):81–7.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Papadavid E, Economidou J, Psarra A, Kapsimali V, Mantzana V, Antoniou C, et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2003;148(4):709–18.

    Article  CAS  PubMed  Google Scholar 

  17. Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma TH2 cytokines from malignant cells suppress TH1 in L-CTCL. Clin Cancer Res. 2013;19(14):3755–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015;125(18):2798–805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S, et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood. 1996;88(4):1383–9.

    Article  CAS  PubMed  Google Scholar 

  20. Suga H, Sugaya M, Miyagaki T, Ohmatsu H, Fujita H, Kagami S, et al. Association of nerve growth factor, chemokine (CC motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma. Acta Derm Venereol. 2013;93(2):144–9.

    Article  CAS  PubMed  Google Scholar 

  21. Hashimoto T, Mishra SK, Olivry T, Yosipovitch G. Periostin, an emerging player in itch sensation. J Invest Dermatol. 2021;141(10):2338–43.

    Article  CAS  PubMed  Google Scholar 

  22. Takahashi N, Sugaya M, Suga H, Oka T, Kawaguchi M, Miyagaki T, et al. Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T-cell lymphoma TSLP in cutaneous T-celllLymphoma. Cancer Res. 2016;76(21):6241–52.

    Article  CAS  PubMed  Google Scholar 

  23. Murota H, Lingli Y, Katayama I. Periostin in the pathogenesis of skin diseases. Cell Mol Life Sci. 2017;74:4321–8.

    Article  CAS  PubMed  Google Scholar 

  24. Nakashima C, Ishida Y, Kitoh A, Otsuka A, Kabashima K. Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus. Exp Dermatol. 2019;28(12):1405–11.

    Article  CAS  PubMed  Google Scholar 

  25. Rüdrich U, Gehring M, Papakonstantinou E, Illerhaus A, Engmann J, Kapp A, et al. Eosinophils are a major source of interleukin-31 in bullous pemphigoid. Acta Derm Venereol. 2018;98(8):766–71.

    Article  PubMed  Google Scholar 

  26. Wong L-S, Yen Y-T, Lee C-H. The implications of pruritogens in the pathogenesis of atopic dermatitis. Int J Mol Sci. 2021;22(13):7227.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hashimoto T, Kursewicz CD, Fayne RA, Nanda S, Shah SM, Nattkemper L, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol. 2020;83(1):53–62.

    Article  CAS  PubMed  Google Scholar 

  28. Shimizu K, Andoh T, Makino T, Yoshihisa Y, Mizawa M, Shimizu T. Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression. Eur J Dermatol. 2019;29:268–73.

    Article  CAS  PubMed  Google Scholar 

  29. Kural YB, Su O, Onsun N, Uras AR. Atopy, IgE and eosinophilic cationic protein concentration, specific IgE positivity, eosinophil count in cutaneous T cell lymphoma. Int J Dermatol. 2010;49(4):390–5.

    Article  CAS  PubMed  Google Scholar 

  30. Fredholm S, Gjerdrum LMR, Willerslev-Olsen A, Petersen DL, Nielsen IØ, Kauczok C-S, et al. STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides. Anticancer Res. 2014;34(10):5277–86.

    CAS  PubMed  Google Scholar 

  31. Günther C, Wozel G, Meurer M, Pfeiffer C. Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid. Clin Exp Immunol. 2011;166(2):145–53.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Rabenhorst A, Schlaak M, Heukamp LC, Förster A, Theurich S, von Bergwelt-Baildon M, et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood. 2012;120(10):2042–54.

    Article  CAS  PubMed  Google Scholar 

  33. Eder J, Rogojanu R, Jerney W, Erhart F, Dohnal A, Kitzwögerer M, et al. Mast cells are abundant in primary cutaneous T-cell lymphomas: results from a computer-aided quantitative immunohistological study. PLoS ONE. 2016;11(11): e0163661.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol. 2012;67(4):760–8.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Terhorst-Molawi D, Lohse K, Ginter K, Puhl V, Metz M, Hu M, et al. Mast cells and tryptase are linked to itch and disease severity in mycosis fungoides: results of a pilot study. Front Immunol. 2022;13: 930979.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Ui H, Andoh T, Lee J-B, Nojima H, Kuraishi Y. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. Eur J Pharmacol. 2006;530(1–2):172–8.

    Article  CAS  PubMed  Google Scholar 

  37. Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci. 2003;23(15):6176–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Andoh T, Tsujii K, Kuraishi Y. Increase in pruritogenic kallikrein 5 in the skin of NC mice with chronic dermatitis. Exp Dermatol. 2015;24(12):978–80.

    Article  PubMed  Google Scholar 

  39. Kim HS, Yosipovitch G. The skin microbiota and itch: is there a link? J Clin Med. 2020;9(4):1190.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Lehman JS, Cook-Norris RH, Weed BR, Weenig RH, Gibson LE, Weaver AL, et al. Folliculotropic mycosis fungoides: single-center study and systematic review. Arch Dermatol. 2010;146(6):607–13.

    Article  PubMed  Google Scholar 

  41. Matsui K, Kanai S, Ikuta M, Horikawa S. Mast cells stimulated with peptidoglycan from Staphylococcus aureus augment the development of Th1 cells. J Pharm Pharm Sci. 2018;21(1):296–304.

    Article  PubMed  Google Scholar 

  42. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51:263–92.

    Article  CAS  PubMed  Google Scholar 

  43. Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142(5):1375–90.

    Article  CAS  PubMed  Google Scholar 

  44. Nattkemper LA, Tey HL, Valdes-Rodriguez R, Lee H, Mollanazar NK, Albornoz C, et al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Invest Dermatol. 2018;138(6):1311–7.

    Article  CAS  PubMed  Google Scholar 

  45. Tuzova M, Conniff T, Curiel-Lewandrowski C, Chaney K, Cruikshank W, Wolpowitz D. Absence of full-length neurokinin-1 receptor protein expression by cutaneous T cells: implications for substance P-mediated signaling in mycosis fungoides. Acta Derm Venereol. 2015;95(7):852–4.

    CAS  PubMed  Google Scholar 

  46. Booken N, Heck M, Nicolay J, Klemke C, Goerdt S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164(3):665–7.

    CAS  PubMed  Google Scholar 

  47. Song JS, Tawa M, Chau NG, Kupper TS, LeBoeuf NR. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature. BMC Cancer. 2017;17:1–6.

    Article  CAS  Google Scholar 

  48. Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006;42(8):1014–30.

    Article  PubMed  Google Scholar 

  49. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch Dermatol. 1998;134(8):949–54.

    Article  CAS  PubMed  Google Scholar 

  50. Bingham LG, Noble JW, Davis MD. Wet dressings used with topical corticosteroids for pruritic dermatoses: a retrospective study. J Am Acad Dermatol. 2009;60(5):792–800.

    Article  PubMed  Google Scholar 

  51. Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801–15.

    Article  PubMed  Google Scholar 

  52. Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Zhong CS, Elmariah SB. Phototherapy for itch. Dermatol Clin. 2020;38(1):145–55.

    Article  CAS  PubMed  Google Scholar 

  54. Olsen EA, Hodak E, Anderson T, Carter JB, Henderson M, Cooper K, et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016;74(1):27–58.

    Article  PubMed  Google Scholar 

  55. Phan K, Ramachandran V, Fassihi H, Sebaratnam DF. Comparison of narrowband UV-B with psoralen–UV-A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(3):335–41.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Hooper MJ, Enriquez GL, Veon FL, LeWitt TM, Sweeney D, Green SJ, et al. Narrowband ultraviolet B response in cutaneous T-cell lymphoma is characterized by increased bacterial diversity and reduced Staphylococcus aureus and Staphylococcus lugdunensis. Front Immunol. 2022;13:1022093.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Siakantaris MP, Tsirigotis P, Stavroyianni N, Argyropoulos KV, Girkas K, Pappa V, et al. Management of cutaneous T-cell lymphoma patients with extracorporeal photopheresis: the Hellenic experience. Transfus Apher Sci. 2012;46(2):189–93.

    Article  PubMed  Google Scholar 

  58. Arulogun S, Prince HM, Gambell P, Lade S, Ryan G, Eaton E, et al. Extracorporeal photopheresis for the treatment of Sezary syndrome using a novel treatment protocol. J Am Acad Dermatol. 2008;59(4):589–95.

    Article  PubMed  Google Scholar 

  59. Chen O, He Q, Han Q, Furutani K, Gu Y, Olexa M, et al. Mechanisms and treatments of neuropathic itch in a mouse model of lymphoma. J Clin Invest. 2023;133(4):e160807.

  60. Demierre M-F, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;55(3):543–4.

    Article  PubMed  Google Scholar 

  61. Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol. 2004;50(6):889–91.

    Article  PubMed  Google Scholar 

  62. Bigatà X, Sais G, Soler F. Severe chronic urticaria: response to mirtazapine. J Am Acad Dermatol. 2005;53(5):916–7.

    Article  PubMed  Google Scholar 

  63. Bromberg H, Chang Y, Craig D. Pruritic manifestation of peripheral T cell lymphoma effectively managed with mirtazapine: a case report. J Pain Palliat Care Pharmacother. 2020;34(3):153–4.

    Article  PubMed  Google Scholar 

  64. Maroñas-Jiménez L, Estrach T, Gallardo F, Pérez A, Andrés Borja H, Servitje O, et al. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas. Br J Dermatol. 2018;178(4):e273–4.

    Article  PubMed  Google Scholar 

  65. Zic JA, Straka BT, McGirt LY, Nian H, Yu C, Brown NJ. Aprepitant for the treatment of pruritus in Sézary syndrome: a randomized crossover clinical trial. JAMA Dermatol. 2018;154(10):1221–2.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63(4):680–8.

    Article  CAS  PubMed  Google Scholar 

  67. Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol. 1999;41(4):533–9.

    CAS  PubMed  Google Scholar 

  68. Brune A, Metze D, Luger T, Ständer S. Antipruritic therapy with the oral opioid receptor antagonist naltrexone: open, non-placebo controlled administration in 133 patients. Hautarzt. 2004;55:1130–6.

    Article  CAS  PubMed  Google Scholar 

  69. Khanna R, Kwon CD, Patel SP, Belzberg M, Williams KA, Khanna R, et al. Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: a case series from the Johns Hopkins Itch Clinic. J Am Acad Dermatol. 2020;83(5):1529–33.

    Article  CAS  PubMed  Google Scholar 

  70. Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006;54(3):527–31.

    Article  PubMed  Google Scholar 

  71. Labib A, Ju T, Lipman ZM, Yosipovitch G. Evaluating the effectiveness of intranasal butorphanol in reducing chronic itch. Acta Derm Venereol. 2022;102:adv00729-adv.

    Article  Google Scholar 

  72. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–71.

    Article  CAS  PubMed  Google Scholar 

  73. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581–93.

    CAS  PubMed  Google Scholar 

  74. Morita A, Tateishi C, Muramatsu S, Kubo R, Yonezawa E, Kato H, et al. Efficacy and safety of bexarotene combined with photo (chemo) therapy for cutaneous T-cell lymphoma. J Dermatol. 2020;47(5):443–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Ginsburg E, Hennessy K, Mhaskar R, Seminario-Vidal L. Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: a systematic review and meta-analysis. Dermatol Ther. 2022;35(5): e15418.

    Article  CAS  PubMed  Google Scholar 

  76. Field H, Gao L, Motwani P, Wong HK. Pruritus reduction with systemic anti-lymphoma treatments in patients with cutaneous T cell lymphoma: a narrative review. Dermatol Ther. 2016;6:579–95.

    Article  Google Scholar 

  77. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–15.

    Article  CAS  PubMed  Google Scholar 

  79. Dummer R, Beyer M, Hymes K, Ep** MT, Bernards R, Steinhoff M, et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leukemia Lymphoma. 2012;53(8):1501–8.

    Article  CAS  PubMed  Google Scholar 

  80. Whittaker SJ, Demierre M-F, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–91.

    Article  CAS  PubMed  Google Scholar 

  81. Kim YH, Demierre M-F, Kim EJ, Lerner A, Rook AH, Duvic M, et al. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leukemia Lymphoma. 2013;54(2):284–9.

    Article  CAS  PubMed  Google Scholar 

  82. Poligone B, Rubio-Gonzalez B, Querfeld C. Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: a series of four cases. Dermatol Ther. 2019;32(2): e12804.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Duvic M, Dummer R, Becker JC, Poulalhon N, Romero PO, Bernengo MG, et al. Panobinostat activity in both bexarotene-exposed and-naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49(2):386–94.

    Article  CAS  PubMed  Google Scholar 

  84. Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, et al. A Phase II trial of Belinostat (PXD 101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168(6):811–9.

    Article  CAS  PubMed  Google Scholar 

  85. Child F, Ortiz-Romero P, Alvarez R, Bagot M, Stadler R, Weichenthal M, et al. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016;175(1):80–8.

    Article  CAS  PubMed  Google Scholar 

  86. Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol. 2021;192(4):683–96.

    Article  PubMed  Google Scholar 

  87. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–204.

    Article  CAS  PubMed  Google Scholar 

  88. Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L, et al. Quality of life effect of the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in patients with cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leukemia. 2021;21(2):97–105.

    Article  CAS  Google Scholar 

  89. Ottevanger R, van Beugen S, Evers AW, Willemze R, Vermeer MH, Quint KD. Quality of life in cutaneous T-cell lymphoma patients receiving mogamulizumab: important factors to consider. Cancers. 2022;15(1):32.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101(11):4267–72.

    Article  CAS  PubMed  Google Scholar 

  91. Kennedy G, Seymour J, Wolf M, Januszewicz H, Davison J, McCormack C, et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol. 2003;71(4):250–6.

    Article  CAS  PubMed  Google Scholar 

  92. De Masson A, Guitera P, Brice P, Moulonguet I, Mouly F, Bouaziz JD, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014;170(3):720–4.

    Article  PubMed  Google Scholar 

  93. Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–66.

    Article  CAS  PubMed  Google Scholar 

  94. Lewis DJ, Haun PL, Samimi SS, Vittorio CC, Villasenor-Park J, Barta SK, et al. Brentuximab vedotin for relapsed or refractory Sézary syndrome. JAMA Dermatol. 2021;157(3):317–21.

    Article  PubMed  Google Scholar 

  95. Damaj G, Bouabdallah R, Vey N, Bilger K, Mohty M, Gastaut J. Single-agent thalidomide induces response in T-cell lymphoma. Eur J Haematol. 2005;74(2):169–71.

    Article  CAS  PubMed  Google Scholar 

  96. Oxberry S, Johnson M. Response to thalidomide in chemotherapy-resistant cutaneous T-cell lymphoma. Clin Oncol. 2006;18(1):86–7.

    Article  CAS  Google Scholar 

  97. Sharma D, Kwatra SG. Thalidomide for the treatment of chronic refractory pruritus. J Am Acad Dermatol. 2016;74(2):363–9.

    Article  CAS  PubMed  Google Scholar 

  98. Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A review of the efficacy of thalidomide and lenalidomide in the treatment of refractory prurigo nodularis. Dermatol Ther. 2016;6:397–411.

    Article  Google Scholar 

  99. Brightman L, Demierre M-F. Thalidomide in mycosis fungoides. J Am Acad Dermatol. 2005;52(6):1100–1.

    Article  PubMed  Google Scholar 

  100. Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood. 2014;123(8):1159–66.

    Article  CAS  PubMed  Google Scholar 

  101. Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49(13):2869–76.

    Article  CAS  PubMed  Google Scholar 

  102. Steck O, Bertschi NL, Luther F, van den Berg J, Winkel DJ, Holbro A, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol. 2021;35(6):1331–7.

    Article  CAS  PubMed  Google Scholar 

  103. Mollanazar NK, Savage KT, Pousti BT, Jariwala N, Del Guzzo C, Haun P, et al. Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab. Cutis. 2020;106(3):131–2.

    Article  PubMed  Google Scholar 

  104. Lazaridou I, Ram-Wolff C, Bouaziz J-D, Bégon E, Battistella M, Rivet J, et al. Dupilumab treatment in two patients with cutaneous T-cell lymphomas. Acta Derm Venereol. 2020;100(16):1–2.

    Article  Google Scholar 

  105. Schaefer L, Comfere N, Sokumbi O. Development of cutaneous T-cell lymphoma following biologic treatment: a systematic review. Am J Clin Dermatol. 2023;24(2):153–64.

    Article  Google Scholar 

  106. Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther. 2009;22(5):418–30.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Park A, Wong L, Lang A, Kraus C, Anderson N, Elsensohn A. Cutaneous T-cell lymphoma following dupilumab use: a systematic review. Int J Dermatol. 2023;62(7):862–76.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USA

    Georgia Biazus Soares & Gil Yosipovitch

  2. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Joan Guitart

  3. 5555 Ponce de Leon, Coral Gables, FL, 33146, USA

    Gil Yosipovitch

Authors
  1. Georgia Biazus Soares
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan Guitart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gil Yosipovitch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gil Yosipovitch.

Ethics declarations

Funding

No external funding was received to assist with preparation of this article.

Conflicts of Interest

Georgia Biazus Soares has no conflicts of interest that are directly relevant to the content of this article. Joan Guitart is a consultant for Kyowa Kirin and Castle Diagnostics. Gil Yosipovitch serves as an advisory board member for Abbvie, Arcutis, BMS, Cara Therapuetics, GSK, Escient Health, Eli Lilly, Galderma, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi, TreviTherapeutics, and Vifor; has received grants/research funding from Eli Lilly, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Galderma, Escient, Sanofi Regeneron, and Celldex; and has received pathways grants as an Investigator for Regeneron Pharmaceuticals, Inc. and Sanofi.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Availability of Data and Material

Not applicable.

Code Availability

Not applicable.

Author’s Contributions

Conceptualization: GBS, GY; writing, original draft preparation: GBS; writing, review and editing: JG, GY.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biazus Soares, G., Guitart, J. & Yosipovitch, G. What’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus. Am J Clin Dermatol 25, 67–77 (2024). https://doi.org/10.1007/s40257-023-00823-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-023-00823-2

Search

Navigation